Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

A single cystatin C determination before coronary angiography can predict short and long-term adverse events.

Budano C, Andreis A, Filippo O, Bissolino A, Lanfranco G, Usmiani T, Gai M, Levis M, Bergamasco L, Marra S, Rinaldi M, Ferrari GM.

Int J Cardiol. 2019 Oct 8. pii: S0167-5273(19)31697-3. doi: 10.1016/j.ijcard.2019.09.069. [Epub ahead of print]

PMID:
31619362
2.

A prospective study of peri-transplant sorafenib for FLT3-ITD AML patients undergoing allogeneic transplantation.

Pratz KW, Rudek MA, Smith BD, Karp J, Gojo I, Dezern A, Jones RJ, Greer J, Gocke C, Baer MR, Duong VH, Rosner G, Zahurak M, Wright JJ, Emadi A, Levis M; ETCTN-8922 study team.

Biol Blood Marrow Transplant. 2019 Sep 21. pii: S1083-8791(19)30634-2. doi: 10.1016/j.bbmt.2019.09.023. [Epub ahead of print]

PMID:
31550496
3.

Midostaurin for patients with acute myeloid leukemia and FLT3 mutations.

Levis MJ.

Clin Adv Hematol Oncol. 2019 Jun;17(6):323-325. No abstract available.

PMID:
31437132
4.

Correction: Cyaphide-alkynyl complexes: metal-ligand conjugation and the influence of remote substituents.

Furfari SK, Leech MC, Trathen N, Levis MC, Crossley IR.

Dalton Trans. 2019 Sep 14;48(34):13101. doi: 10.1039/c9dt90184a. Epub 2019 Aug 15.

PMID:
31414091
5.

Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction.

Hambley BC, Norsworthy KJ, Jasem J, Zimmerman JW, Shenderov E, Webster JA, Showel MM, Gondek LP, Dalton WB, Prince G, Gladstone DE, Streiff MB, Pratz KW, Gojo I, Ghiaur G, Levis MJ, Smith BD, DeZern AE.

Leuk Res. 2019 Aug;83:106174. doi: 10.1016/j.leukres.2019.106174. Epub 2019 Jun 21. No abstract available.

PMID:
31255938
6.

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.

Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ.

Lancet Oncol. 2019 Jul;20(7):984-997. doi: 10.1016/S1470-2045(19)30150-0. Epub 2019 Jun 4. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31175001
7.

Multi-cellular engineered living systems: building a community around responsible research on emergence.

Sample M, Boulicault M, Allen C, Bashir R, Hyun I, Levis M, Lowenthal C, Mertz D, Montserrat N, Palmer MJ, Saha K, Zartman J.

Biofabrication. 2019 Jul 10;11(4):043001. doi: 10.1088/1758-5090/ab268c.

PMID:
31158828
8.

Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin's lymphoma patients.

Levis M, Filippi AR, Fiandra C, De Luca V, Bartoncini S, Vella D, Ragona R, Ricardi U.

Radiother Oncol. 2019 Sep;138:52-58. doi: 10.1016/j.radonc.2019.05.009. Epub 2019 May 27.

PMID:
31146071
9.

Applying radiation protection and safety in radiotherapy.

Magrini SM, Pasinetti N, Belgioia L, Triggiani L, Levis M, Ricardi U, Corvò R.

Radiol Med. 2019 Aug;124(8):777-782. doi: 10.1007/s11547-019-01043-7. Epub 2019 May 18.

PMID:
31104276
10.

Microfluidics on the fly: Inexpensive rapid fabrication of thermally laminated microfluidic devices for live imaging and multimodal perturbations of multicellular systems.

Levis M, Kumar N, Apakian E, Moreno C, Hernandez U, Olivares A, Ontiveros F, Zartman JJ.

Biomicrofluidics. 2019 Apr 26;13(2):024111. doi: 10.1063/1.5086671. eCollection 2019 Mar.

PMID:
31065310
11.

Cyaphide-alkynyl complexes: metal-ligand conjugation and the influence of remote substituents.

Furfari SK, Leech MC, Trathen N, Levis MC, Crossley IR.

Dalton Trans. 2019 Jun 21;48(23):8131-8143. doi: 10.1039/c9dt01071h. Epub 2019 May 7. Erratum in: Dalton Trans. 2019 Sep 14;48(34):13101.

PMID:
31062801
12.

FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?

Levis MJ, Chen YB, Hamadani M, Horowitz MM, Jones RJ; Blood and Marrow Transplant Clinical Trials Network.

J Clin Oncol. 2019 Jul 1;37(19):1604-1607. doi: 10.1200/JCO.19.00321. Epub 2019 Apr 29. No abstract available.

PMID:
31034300
13.

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia - results from an international collaborative study.

Kayser S, Hills RK, Luskin MR, Brunner AM, Terré C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Ráčil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Krämer A, Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Röllig C, Tallman MS, Estey EH, Müller-Tidow C, Russell NH, Schlenk RF, Levis MJ.

Haematologica. 2019 Apr 19. pii: haematol.2018.208678. doi: 10.3324/haematol.2018.208678. [Epub ahead of print]

14.

Arsenic and old FLT3.

Levis M.

Blood. 2019 Mar 28;133(13):1392-1393. doi: 10.1182/blood-2019-02-899286. No abstract available.

PMID:
30923106
15.

Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors.

Chang YT, Hernandez D, Alonso S, Gao M, Su M, Ghiaur G, Levis MJ, Jones RJ.

Blood Adv. 2019 Mar 26;3(6):908-916. doi: 10.1182/bloodadvances.2018022921.

16.

Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG.

Binkley MS, Brady JL, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Ahmed S, MacManus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova YM, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Mikhaeel NG, Hoppe RT.

Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):522-529. doi: 10.1016/j.ijrobp.2019.03.004. Epub 2019 Mar 8.

PMID:
30858143
17.

Decoding Calcium Signaling Dynamics during Drosophila Wing Disc Development.

Brodskiy PA, Wu Q, Soundarrajan DK, Huizar FJ, Chen J, Liang P, Narciso C, Levis MK, Arredondo-Walsh N, Chen DZ, Zartman JJ.

Biophys J. 2019 Feb 19;116(4):725-740. doi: 10.1016/j.bpj.2019.01.007. Epub 2019 Jan 11.

PMID:
30704858
18.

Targeting FLT3 mutations in AML: review of current knowledge and evidence.

Daver N, Schlenk RF, Russell NH, Levis MJ.

Leukemia. 2019 Feb;33(2):299-312. doi: 10.1038/s41375-018-0357-9. Epub 2019 Jan 16. Review.

19.

Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG.

Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Mac Manus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova Y, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Hoppe RT, Mikhaeel NG.

Blood. 2019 Jan 17;133(3):237-245. doi: 10.1182/blood-2018-04-843540. Epub 2018 Nov 16. Erratum in: Blood. 2019 Jul 18;134(3):331.

PMID:
30446493
20.

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3.

Nagai K, Hou L, Li L, Nguyen B, Seale T, Shirley C, Ma H, Levis M, Ghiaur G, Duffield A, Small D.

Oncotarget. 2018 Aug 31;9(68):32885-32899. doi: 10.18632/oncotarget.25972. eCollection 2018 Aug 31.

21.

Clinical implications of molecular markers in acute myeloid leukemia.

Kayser S, Levis MJ.

Eur J Haematol. 2019 Jan;102(1):20-35. doi: 10.1111/ejh.13172. Epub 2018 Oct 23. Review.

PMID:
30203623
22.

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide.

Schoch LK, Cooke KR, Wagner-Johnston ND, Gojo I, Swinnen LJ, Imus P, Fuchs EJ, Levis M, Ambinder RF, Jones RJ, Gladstone DE.

Blood Adv. 2018 Sep 11;2(17):2226-2229. doi: 10.1182/bloodadvances.2018019208.

23.

Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity.

Lau BW, Huh K, Madero-Marroquin R, De Marchi F, Lim Y, Wang Q, Lobo F, Marchionni L, Smith DB, DeZern A, Levis MJ, Aplan PD, Matsui W, Gondek LP.

Oncogene. 2019 Jan;38(5):687-698. doi: 10.1038/s41388-018-0431-9. Epub 2018 Aug 31.

24.

Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.

Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F.

Am J Hematol. 2018 Sep;93(9):1136-1141. doi: 10.1002/ajh.25198. Epub 2018 Aug 31.

25.

Diagnosis and management of Cornelia de Lange syndrome: first international consensus statement.

Kline AD, Moss JF, Selicorni A, Bisgaard AM, Deardorff MA, Gillett PM, Ishman SL, Kerr LM, Levin AV, Mulder PA, Ramos FJ, Wierzba J, Ajmone PF, Axtell D, Blagowidow N, Cereda A, Costantino A, Cormier-Daire V, FitzPatrick D, Grados M, Groves L, Guthrie W, Huisman S, Kaiser FJ, Koekkoek G, Levis M, Mariani M, McCleery JP, Menke LA, Metrena A, O'Connor J, Oliver C, Pie J, Piening S, Potter CJ, Quaglio AL, Redeker E, Richman D, Rigamonti C, Shi A, Tümer Z, Van Balkom IDC, Hennekam RC.

Nat Rev Genet. 2018 Oct;19(10):649-666. doi: 10.1038/s41576-018-0031-0. Review.

PMID:
29995837
26.

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ.

Blood. 2018 Aug 9;132(6):598-607. doi: 10.1182/blood-2018-01-821629. Epub 2018 Jun 6.

27.

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M.

Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.

PMID:
29859851
28.

Plan optimization for mediastinal radiotherapy: Estimation of coronary arteries motion with ECG-gated cardiac imaging and creation of compensatory expansion margins.

Levis M, De Luca V, Fiandra C, Veglia S, Fava A, Gatti M, Giorgi M, Bartoncini S, Cadoni F, Garabello D, Ragona R, Filippi AR, Ricardi U.

Radiother Oncol. 2018 Jun;127(3):481-486. doi: 10.1016/j.radonc.2018.04.014. Epub 2018 May 2.

PMID:
29729845
29.

A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations.

Levis MJ, Perl AE, Altman JK, Gocke CD, Bahceci E, Hill J, Liu C, Xie Z, Carson AR, McClain V, Stenzel TT, Miller JE.

Blood Adv. 2018 Apr 24;2(8):825-831. doi: 10.1182/bloodadvances.2018015925.

30.

The current therapeutic landscape of FLT3 inhibitors.

Levis M.

Blood Adv. 2017 Oct 10;1(22):1944. doi: 10.1182/bloodadvances.2017007682. eCollection 2017 Oct 10. No abstract available.

31.

Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide.

Kasamon YL, Ambinder RF, Fuchs EJ, Zahurak M, Rosner GL, Bolaños-Meade J, Levis MJ, Gladstone DE, Huff CA, Swinnen LJ, Matsui WH, Borrello I, Brodsky RA, Jones RJ, Luznik L.

Blood Adv. 2017;1(4):288-292. doi: 10.1182/bloodadvances.2016002766. Epub 2017 Jan 6.

32.

Advances in targeted therapy for acute myeloid leukaemia.

Kayser S, Levis MJ.

Br J Haematol. 2018 Feb;180(4):484-500. doi: 10.1111/bjh.15032. Epub 2017 Nov 28. Review.

33.

Emerging molecular predictive and prognostic factors in acute myeloid leukemia.

McCurdy SR, Levis MJ.

Leuk Lymphoma. 2018 Sep;59(9):2021-2039. doi: 10.1080/10428194.2017.1393669. Epub 2017 Nov 2. Review.

PMID:
29095060
34.

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.

Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, DeAngelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, Stone RM, Larson RA.

Blood Adv. 2017 Jan 24;1(5):331-340. doi: 10.1182/bloodadvances.2016003053.

35.

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.

Fathi AT, Blonquist TM, Hernandez D, Amrein PC, Ballen KK, McMasters M, Avigan DE, Joyce R, Logan EK, Hobbs G, Brunner AM, Joseph C, Perry AM, Burke M, Behnan T, Foster J, Bergeron MK, Moran JA, Ramos AY, Som TT, Rae J, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Levis MJ.

Cancer. 2018 Jan 15;124(2):306-314. doi: 10.1002/cncr.31038. Epub 2017 Sep 28. Erratum in: Cancer. 2018 May 15;124(10 ):2258.

36.

Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.

Kayser S, Levis MJ, Schlenk RF.

Expert Rev Clin Pharmacol. 2017 Nov;10(11):1177-1189. doi: 10.1080/17512433.2017.1387051. Epub 2017 Oct 10. Review.

PMID:
28960095
37.

Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.

Bruner JK, Ma HS, Li L, Qin ACR, Rudek MA, Jones RJ, Levis MJ, Pratz KW, Pratilas CA, Small D.

Cancer Res. 2017 Oct 15;77(20):5554-5563. doi: 10.1158/0008-5472.CAN-16-2593. Epub 2017 Sep 18.

38.

Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.

Norsworthy KJ, DeZern AE, Tsai HL, Hand WA, Varadhan R, Gore SD, Gojo I, Pratz K, Carraway HE, Showel M, McDevitt MA, Gladstone D, Ghiaur G, Prince G, Seung AH, Benani D, Levis MJ, Karp JE, Smith BD.

Leuk Res. 2017 Oct;61:25-32. doi: 10.1016/j.leukres.2017.08.009. Epub 2017 Aug 30. Review.

39.

Health-Related Quality of Life of Patients with Acute Myeloid Leukemia: A Systematic Literature Review.

Korol EE, Wang S, Johnston K, Ravandi-Kashani F, Levis M, van Nooten F.

Oncol Ther. 2017;5(1):1-16. doi: 10.1007/s40487-016-0039-6. Epub 2017 Jan 27. Review.

40.

Contrast-induced kidney injury: how does it affect long-term cardiac mortality?

Andreis A, Budano C, Levis M, Garrone P, Usmiani T, D'Ascenzo F, De Filippo O, D'Amico M, Bergamasco L, Biancone L, Marra S, Colombo A, Gaita F.

J Cardiovasc Med (Hagerstown). 2017 Nov;18(11):908-915. doi: 10.2459/JCM.0000000000000543.

PMID:
28678146
41.

Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.

Ghiaur G, Levis M.

Hematol Oncol Clin North Am. 2017 Aug;31(4):681-692. doi: 10.1016/j.hoc.2017.04.005. Epub 2017 May 18. Review.

42.

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M.

Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Lancet Oncol. 2018 Jul;19(7):e335. Lancet Oncol. 2019 Jun;20(6):e293.

43.

FLT3 dancing on the stem cell.

Levis M.

J Exp Med. 2017 Jul 3;214(7):1857-1859. doi: 10.1084/jem.20171056. Epub 2017 Jun 21.

44.

Midostaurin approved for FLT3-mutated AML.

Levis M.

Blood. 2017 Jun 29;129(26):3403-3406. doi: 10.1182/blood-2017-05-782292. Epub 2017 May 25. Review.

PMID:
28546144
45.

Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.

Smith CC, Paguirigan A, Jeschke GR, Lin KC, Massi E, Tarver T, Chin CS, Asthana S, Olshen A, Travers KJ, Wang S, Levis MJ, Perl AE, Radich JP, Shah NP.

Blood. 2017 Jul 6;130(1):48-58. doi: 10.1182/blood-2016-04-711820. Epub 2017 May 10.

46.

The Future of Targeting FLT3 Activation in AML.

Leick MB, Levis MJ.

Curr Hematol Malig Rep. 2017 Jun;12(3):153-167. doi: 10.1007/s11899-017-0381-2. Review.

PMID:
28421420
47.

Optimal Therapy for Early-Stage Hodgkin's Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy.

Filippi AR, Levis M, Parikh R, Hoppe B.

Curr Oncol Rep. 2017 May;19(5):34. doi: 10.1007/s11912-017-0592-7. Review.

PMID:
28365830
48.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J, Žák P, Szotkowski T, Grimwade D, Russell NH, Walter RB, Estey EH, Westermann J, Görner M, Benner A, Krämer A, Smith BD, Burnett AK, Thiede C, Röllig C, Ho AD, Ehninger G, Schlenk RF, Tallman MS, Levis MJ, Platzbecker U.

Leukemia. 2017 Nov;31(11):2347-2354. doi: 10.1038/leu.2017.92. Epub 2017 Mar 21.

49.

FLT3 as a marker of minimal residual disease: Time to re-think?

Levis M.

Am J Hematol. 2017 Apr;92(4):329-330. doi: 10.1002/ajh.24667. Epub 2017 Feb 21. No abstract available.

50.

FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.

Nguyen B, Williams AB, Young DJ, Ma H, Li L, Levis M, Brown P, Small D.

Oncotarget. 2017 Feb 14;8(7):10931-10944. doi: 10.18632/oncotarget.14539.

Supplemental Content

Support Center